Comparing the current results to its competitors, Sera Prognostics Inc reported Revenue increase in the 2 quarter 2026 by 76.47 % year on year. The sales growth was above Sera Prognostics Inc 's competitors' average revenue growth of 13.4 %, achieved in the same quarter.
Bioaffinity Technologies Inc is a biotechnology company specializing in developing and commercializing diagnostics for various medical conditions. They utilize their patented platform technology, Affinity™, which enables the detection of cancer and other diseases at an early stage through the use of biomarkers. The company focuses on licensing their technology and partnering with diagnostic companies, aiming to provide accurate, non-invasive, and cost-effective diagnostic solutions.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Fortrea Holdings Inc is a company that operates through its subsidiaries in the business of software and technology services, providing innovative solutions and products to its clients. Its business model focuses on developing and delivering custom software applications, digital platforms, and consulting services to cater to the specific needs of various industries.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Sera Prognostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sera Prognostics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
